A follow-up study shows no new infections caused by patients with repeat positive of COVID-19 in

Wuhan

Xiaomin Wu^{1†}, Zengmiao Wang^{2†*}, Zhenyu He^{1†*}, Yapin Li^{3†}, Yating Wu¹, Huaiji Wang¹, Yonghong Liu², Fanghua Hao⁴, Huaiyu Tian^{2†}

¹ Wuhan Center for Disease Control and Prevention, Wuhan, China;

² State Key Laboratory of Remote Sensing Science, Center for Global Change and Public Health, College of Global Change and Earth System Science, Beijing Normal University, Beijing, China;

³ Central Theater Center for Disease Control and Prevention of PLA, Beijing, China;

⁴ Central China Normal University, Wuhan, China;

†These authors contributed equally to this work.

*Corresponding author. Email: hosan9174@163.com (Z.H.), wangzengmiao@gmail.com (Z.W.);

A follow-up study shows no new infections caused by patients with repeat positive of COVID-19 in

Wuhan

Abstract

Background: It has been reported that a few recovered COVID-19 patients could suffer repeat positive, testing positive for the SARS-CoV-2 virus again after they were discharged from hospital. Understanding the epidemiological characteristics of patients with repeat positive is vital in preventing a second wave of COVID-19.

Methods: In this study, the epidemiological and clinical features for 20,280 COVID-19 patients from multiple centers between 31 December 2019 and 4 August 2020 in Wuhan were collected and followed. In addition, the RT-qPCR testing results for 4,079 individuals who had close contact with the patients suffering repeat positive were also obtained.

Results: 2,466 (12.16%) of 20,280 patients presented with a repeat positive of SARS-CoV-2 after they were discharged from hospital. 4,079 individuals had close contact with them. The PCR result were negative for the 4,079 individuals.

Conclusions: By a follow-up study in Wuhan, we show the basic characteristics of patients with repeat positive and no new infections caused by patients with repeat positive of COVID-19.

Keywords: COVID-19, Repeat positive, Close contact, Secondary infection

Background

The ongoing severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) pandemic has caused more than 49 million cases of coronavirus disease 2019 (COVID-19) illness and over 1.2 million people were dead due to the coronavirus worldwide by November 2020(1). Guidelines from WHO on clinical management recommend that a clinically recovered COVID-19 patient should test negative for the virus twice, with testing supervised by trained professionals and conducted at least 24 hours apart, before being discharged from the hospital. It has been reported that a few recovered COVID-19 patients could suffer repeat positive, testing positive for the virus again within the 14-day isolation period(2–4). The number of patients reported to have had repeat positive of COVID-19 is small and the duration of follow-up has been short. Understanding the epidemiological characteristics of patients with repeat positive is vital in

preventing a second wave of COVID-19.

Methods

Study description

The COVID-19 outbreak was first reported in Wuhan(5) and had lasted more than 3 months by 5 April 2020, after which date there were no further locally acquired infections. During the outbreak in Wuhan, there were a total of 50333 confirmed COVID-19 cases with 3869 deaths, and 46464 patients have been clinically cured and discharged according to WHO guidelines(6). After being discharged from hospital, patients in Wuhan continue to be isolated in rehabilitation center for 14 days and at home for another 14 days to prevent reinfection, followed up and then regularly revisited at hospitals. Here we collect all the information on SARS-CoV-2 patients with repeat positive between 31 December 2019 and 4 August 2020 across 84 hospitals in Wuhan, presenting epidemiological and clinical features.

Data collection

Cases of COVID-19 was diagnosed and the illness severity was defined according to the Chinese management guideline for COVID-19 (the sixth edition) published by National Health Commission of the People's Republic of China. All first diagnosis cases of COVID-19 were confirmed according to positive respiratory RT-PCR tests. Repeat positive were confirmed by digestive (anal swab) and respiratory positive RT-PCR tests. Samples by Nasopharyngeal swab or Pharynx swab were collected and tested for SARS-CoV-2, following WHO guidelines.

The discharge criteria of the recovered patients included: body temperature is back to normal for more than

three days, respiratory symptoms improve obviously, pulmonary imaging shows obvious absorption of inflammation, and nucleic acid tests negative for respiratory tract pathogen twice consecutively (sampling interval being at least 24 hours). Those who meet the above criteria can be discharged. After discharge, it is recommended for the patients to continue 14 days of isolation management and health monitoring, wear a mask, live in a single room with good ventilation. The patients are required to return to the hospitals for follow-up and revisit in two and four weeks after discharge.

Statistical analysis

In this study, categorical variables were presented as numbers and percentages, and continuous variables were presented using median (interquartile range, IQR). Student *t*-test was used to compare continuous variables in two groups. Multivariate logistic regression model was used to determine the associated factors. All statistical analyses were performed using R version 3.4.1. *P* value less than 0.05 was considered statistically significant.

Results

In total, 20,280 patients were collected and followed. Among them, 2,466(12.16%) patients presented with a repeat positive of SARS-CoV-2 after they were discharged from hospital. The demographic and epidemiological characteristics of these patients are similar to the first infections (shown in Table 1). The median treatment time for patients without repeat positive in hospital was 15.71 days (interquartile range [IQR], 9.83 to 23.21) and the median treatment time for the first infection in patients with a repeat positive was 18.54 days (interquartile range [IQR], 11.96 to 27.04). The treatment time for first infection in patients with a repeat positive was significantly longer than that in patients without a repeat positive

(p-value <0.001 from Student *t*-test). For the repeat positive, the median treatment time was 10.63 days (interquartile range [IQR], 7.67 to 15.63). The treatment time for the repeat positive was shorter than that for the first infection among the patients with a repeat positive. The median time from discharge from hospital to the start of a second positive was 11.00 days (IQR, 9.00 to 17.00). A total of 56.12% were female. The median age of the patients was 56.00 years (IQR, 42.25 to 65.00). In addition, more than half of the patients (50.9%, n=1256) were aged between 50 and 70 years (accounted for 15.6% of the total population in Wuhan). Symptoms of first infection for patients with repeat positive were 0.24% asymptomatic, 49.67% mild, 35.59% moderate, 12.05% severe and 2.40% critical. For the symptoms of the second positive, of 2,466, 193(7.83%) patients had fever, cough or shortness of breath. Specifically, 158(6.41%) patients had fever, 59 (2.39%) patients had cough and 18(0.73%) patients had shortness of breath. 32(1.30%) patients had both fever and cough. 1(0.04%) patient had both cough and shortness of breath. 9 (0.36%) patients had both fever and shortness of breath. No patients had three types of symptom at the same time. 11 of 2,466 patients were passed away.

A logistic regression model was used to check the factors related to a repeat positive. The age had no effects (coeff.=0.001, $P=0.379$) on the probability of a repeat positive. Interestingly, we found that the gender had a significantly role (coeff.=-0.119, $P=0.005$). The males had a lower risk of developing a repeat positive compared to females.

To investigate whether the patients with repeat positive can cause the new infections, we collected the PCR results for the people who had close contact with patients with repeat positive. Of 2,466 patients with repeat positive, 1,201 patients were tested positive in rehabilitation center and there were no individuals

who had close contact with them. So these 1,201 patients had no chance to infect healthy persons. 1,265 patients were tested positive after they went back home. 4,079 individuals had close contact with them. The PCR result were negative for the 4,079 individuals. This indicates that the patients with repeat positive don't cause new infections.

Discussion

Although several studies have reported patients with repeat positive of COVID-19, most are based on a limited sample and the proportion of SARS-CoV-2 reactivation ranged from 9% (5/55)(2) to 14.5% (38/262)(4). This study retrospectively analyzed clinical data in a cohort of 20,280 patients in Wuhan. We confirmed that in 12.16% of COVID-19 patients, SARS-CoV-2 could be isolated again after discharge from hospital. The time from SARS-CoV-2 negative to positive ranged from 1 to 165 days, suggesting that recovered patients still may be virus carriers and require additional round of viral detection and isolation. Note that the repeat positive could also be the virus fragment coming from the first infection because the PCR test only detects the fragments of SARS-CoV-2 genome, not viable virus. Another study shown that no infectious strain could be obtained by culture and no full-length viral genomes could be sequenced from 87 re-positive cases(7). These may explain why there were no secondary infection. Although this study does not completely exclude the possibility of reinfection, however, given the 28-day isolation and 84.07% (2058/2448) of the repeat positive occurred during this isolation in Wuhan, most of these patients have apparently not caused new infections after discharge from hospital in Wuhan.

Conclusions

In this follow-up study in Wuhan, we show the basic characteristics of patients with repeat positive and no

new infections caused by patients with repeat positive of COVID-19.

Term definition

Patient with repeat positive: the patient was test positive for SARS-CoV-2 again after being discharged from hospital.

Treatment time: time interval of a patient being hospitalized.

Close contact: the individuals living in the same houses with the patients.

Ethics approval and consent to participate

The epidemiological and clinical data collection was exempt from Institutional Review Boards, because it was part of public health investigation for COVID-19, issued by the National Health Commission of the People's Republic of China

(<http://www.nhc.gov.cn/jkj/s3577/202003/4856d5b0458141fa9f376853224d41d7.shtml>). This study was approved by the Institutional Review Boards from Wuhan Center for Disease Control and Prevention.

Consent for publication

Not applicable.

Availability of data and materials

The data supporting the findings of this study are available within the article.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by the Major Prevention Projects of Hubei Province Health Committee (WJ2019H303); Beijing Natural Science Foundation (JQ18025); Beijing Advanced Innovation Program for Land Surface Science; National Natural Science Foundation of China (81673234); Young Elite Scientist Sponsorship Program by CAST (YESS)(2018QNRC001). HT acknowledge support from the Oxford Martin School. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author contributions

X.W., F.H., Y.L., H.T, Z.H., H.W. designed the study. X.W., Y.W., Z.H. collected the statistical data. Y.L. and Z.W conducted the analyses. H.T. wrote the manuscript. All authors read and approved the manuscript.

Acknowledgements

We thank the many thousands of CDC staff and local health workers in China who collected data.

References

1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time [Internet]. Vol. 20, The Lancet Infectious Diseases. Lancet Publishing Group; 2020 [cited 2020 Oct 29]. p. 533–4. Available from: <https://www.who.int/china/news/>
2. Ye G, Pan Z, Pan Y, Deng Q, Chen L, Li J, et al. Clinical characteristics of severe acute respiratory

syndrome coronavirus 2 reactivation. *J Infect.* 2020 May 1;80(5):e14–7.

3. Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, et al. Positive RT-PCR Test Results in Patients Recovered from COVID-19 [Internet]. Vol. 323, *JAMA - Journal of the American Medical Association*. American Medical Association; 2020 [cited 2020 Oct 4]. p. 1502–3. Available from: <http://www.nhc.gov.cn/yzygj/s7653p/202002/>
4. An J, Liao X, Xiao T, Qian S, Yuan J, Ye H, et al. Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test. [cited 2020 Oct 4]; Available from: <https://doi.org/10.1101/2020.03.26.20044222>
5. Tian H, Liu Y, Li Y, Wu CH, Chen B, Kraemer MUG, et al. An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China. *Science* (80-) [Internet]. 2020 May 8 [cited 2020 Sep 7];368(6491):638–42. Available from: <http://science.sciencemag.org/>
6. Organization WH. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020 [Internet]. Geneva PP - Geneva: World Health Organization; Available from: <https://apps.who.int/iris/handle/10665/331446>
7. Lu J, Peng J, Xiong Q, Liu Z, Lin H, Tan X, et al. Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR. *EBioMedicine* [Internet]. 2020 Sep 1 [cited 2020 Oct 4];59:102960. Available from: <https://doi.org/10.1016/j.ebiom.2020.102960>

Table 1. Characteristics of SARS-CoV-2 positive cases by presence of repeat positive, Wuhan, China, December 2019-August 2020.

Characteristic	Total patients (N=20,280)	Patient with repeat positive (N=2,466)	Patient without repeat positive (N= 17,814)
Treatment time for first infection, median (IQR)	15.96(9.96-23.75) ⁵	18.54(11.96- 27.04) ¹	15.71(9.83-23.21) ³
Days from discharge from hospital to repeat positive, median (IQR)	NA	11.00(9.00-17.00) ²	NA
Treatment time for second infection, median (IQR)	NA	10.63(7.67-15.63) ⁴	NA
Sex, no. (%)			
Male	9433(46.51%)	1082(43.88%)	8351(46.88%)
Female	10847(53.49%)	1384(56.12%)	9463(53.12%)
Age, no. (%)			
0 ~9	124(0.61%)	6(0.24%)	118(0.66%)

It is made available under a [CC-BY 4.0 International license](#).

10 ~19	172(0.85%)	23(0.93%)	149(0.84%)
20 ~29	913(4.50%)	142(5.76%)	771(4.33%)
30 ~39	2662(13.13%)	335(13.58%)	2327(13.06%)
40 ~49	3572(17.61%)	370(15.00%)	3202(17.97%)
50 ~59	4941(24.36%)	588(23.84%)	4353(24.44%)
60 ~69	5319(26.22%)	668(27.09%)	4651(26.11%)
70 ~79	1973(9.73%)	254(10.30%)	1719(9.65%)
>=80	562(2.77%)	80(3.24%)	482(2.71%)
Symptoms of first infection,	*	*	
no. (%)			
Asymptomatic	543(2.68%)	6(0.24%)	537(3.01%)
Mild	10304(50.83%)	1220(49.67%)	9084(51.00%)
Moderate	6614(32.63%)	874(35.59%)	5740(32.22%)
Severe	2365(11.67%)	296(12.05%)	2069(11.61%)
Critical	379(1.87%)	59(2.40%)	320(1.80%)

¹650 cases were removed due to lack of detailed information

²18 cases were removed due to lack of detailed information

³4447 cases were removed due to lack of detailed information

⁴1841 cases were removed due to lack of detailed information

⁵5097 cases were removed due to lack of detailed information

*10 cases were removed due to lack of detailed information

It is made available under a [CC-BY 4.0 International license](#).